Trials / Completed
CompletedNCT05135221
Combination Therapy With Two Biologicals
Combining Biological Therapies in Patients With Inflammatory Bowel Disease: a Finnish Multi-centre Study.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 16 (actual)
- Sponsor
- Tampere University Hospital · Academic / Other
- Sex
- All
- Age
- 16 Years
- Healthy volunteers
- Accepted
Summary
The efficacy and safety of dual biological therapy.
Detailed description
Data of all patients treated with the combination of two biologicals in four Finnish tertiary centres were collected and analysed. Inclusion criteria were simultaneous use of two biological treatments (infliximab, adalimumab, golimumab, vedolizumab or ustekinumab), age 16 years or over and follow-up for at least induction period after introduction of second biological therapy. The primary outcome was effectiveness, defined as remission assessed by physician after at least four months of DBT. The secondary outcome was safety defined by any adverse events or infection complications during DBT.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | dual biological therapy | Simultaneous use of two biologicals. |
Timeline
- Start date
- 2015-01-01
- Primary completion
- 2019-12-30
- Completion
- 2021-10-01
- First posted
- 2021-11-26
- Last updated
- 2021-11-26
Locations
1 site across 1 country: Finland
Source: ClinicalTrials.gov record NCT05135221. Inclusion in this directory is not an endorsement.